Twist Bioscience (NASDAQ:TWST) Shares Down 5.8% – Here’s Why

Twist Bioscience Co. (NASDAQ:TWST) shares traded down 5.8% during trading on Monday . The company traded as low as $49.12 and last traded at $49.26. 125,025 shares were traded during trading, a decline of 84% from the average session volume of 769,663 shares. The stock had previously closed at $52.30.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on TWST shares. JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 4th. Scotiabank raised their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a report on Tuesday, February 4th. Leerink Partners boosted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Barclays decreased their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Finally, Robert W. Baird lifted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $53.80.

Twist Bioscience Stock Down 5.0 %

The company’s fifty day simple moving average is $48.79 and its 200 day simple moving average is $45.99. The company has a quick ratio of 4.54, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience’s revenue was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.75) earnings per share. On average, equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Activity

In other Twist Bioscience news, CFO Adam Laponis sold 5,886 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the sale, the chief financial officer now owns 110,096 shares of the company’s stock, valued at $4,762,752.96. This represents a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $39,776.10. Following the transaction, the insider now directly owns 112,221 shares in the company, valued at $5,538,106.35. This trade represents a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,180 shares of company stock worth $1,821,971. 3.01% of the stock is currently owned by corporate insiders.

Institutional Trading of Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the business. Massachusetts Financial Services Co. MA increased its holdings in shares of Twist Bioscience by 215.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after buying an additional 20,035 shares during the period. Barclays PLC increased its stake in Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after purchasing an additional 104,420 shares during the period. FMR LLC lifted its position in Twist Bioscience by 6.0% in the third quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after purchasing an additional 12,327 shares during the last quarter. Avanza Fonder AB purchased a new stake in shares of Twist Bioscience during the fourth quarter valued at approximately $1,059,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Twist Bioscience by 128.1% in the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock worth $1,718,000 after purchasing an additional 21,357 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.